Protocol Ledger

NCT07187531 · Phase II · RECRUITING

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Interventional Phase II clinical trial protocol NCT07187531 sponsored by SAb Biotherapeutics in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-25 Enrollment: 159 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07187531
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)159 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07187531
Protocol FieldVerified Registry Value
NCT IdentifierNCT07187531
Consolidated Lead SponsorSAb Biotherapeutics
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment159 participants (ESTIMATED)
Registered Start Date2025-11-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI